Lactobacillus reuteri in management of Helicobacter pylori infection in dyspeptic patients: A double-blind placebo-controlled randomized clinical trial

Therapeutic Advances in Gastroenterology

Volumn 7, Issue 1, 2014, Pages 4-13

  Emara, Mohamed H ^a   Mohamed, Salem Y ^a   Abdel Aziz, Hesham R ^a  

^a ZAGAZIG UNIVERSITY   (Egypt)

Author keywords

eradication rate; gastritis; Gastrointestinal Symptom Rating Scale; Helicobacter pylori; Lactobacillus reuteri; triple therapy

Indexed keywords

BACTERIAL ANTIGEN; PLACEBO; PROBIOTIC AGENT;

ADULT; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DIARRHEA; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DYSPEPSIA; ENDOSCOPY; FECES ANALYSIS; FEMALE; GASTRITIS; GASTROINTESTINAL BIOPSY; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL SYMPTOM RATING SCALE; HELICOBACTER INFECTION; HISTOPATHOLOGY; HUMAN; INTESTINE DISTENSION; LACTOBACILLUS REUTERI; MAJOR CLINICAL STUDY; MALE; PATHOGEN CLEARANCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RAPID UREASE TEST; RATING SCALE; TASTE DISORDER; VOMITING; YOUNG ADULT;

EID: 84891098758     PISSN: 1756283X     EISSN: 17562648     Source Type: Journal    
DOI: 10.1177/1756283X13503514     Document Type: Article

References (39)

1. Abordin O. Abdu A. Odetoyin B. Okeke I. Lawal O. Ndububa D. et al. (2007) Antibiotic resistance of Helicobacter pylori from patients in Ile-Ife, South-west, Nigeria. Afr Health Sci 7: 143–147.
2. Byrd J. Yunker C. Xu Q. Sternberg L. Bresalier R. (2000) Inhibition of gastric mucin synthesis by Helicobacter pylori. Gastroenterology 118: 1072–1079.
3. Chauviere G. Coconnier M. Kerneis S. Fourniat J. Servin A. (1992) Adhesion of human Lactobacillus acidophilus strain LB to human enterocyte-like Caco-2 cells. J Gen Microbiol 138: 1689–1696.
4. Cunningham-Rundles S. Ahrne S. Bengmark S. Johann-Liang R. Marshall F. Metakis L. et al. (2000) Probiotics and immune response. Am J Gastroenterol 95: S22–S25.
5. de Francesco V. Zullo A. Hassan C. Della Valle N. Pietrini L. Minenna M. et al. (2004) The prolongation of triple therapy for Helicobacter pylori does not allow reaching therapeutic outcome of sequential scheme: a prospective, randomized study. Dig Liver Dis 36: 322–326.
6. Efrati C. Nicolini G. Cannaviello C. Piazza O'Sed N. Valabrega S. (2012) Helicobacter pylori eradication: sequential therapy and Lactobacillus reuteri supplementation. World J Gastroenterol 18: 6250–6254.
7. Felley C. Corthésy-Theulaz I. Rivero J. Sipponen P. Kaufmann M. Bauerfeind P. et al. (2001) Favourable effect of an acidified milk (LC-1.) on Helicobacter pylori gastritis in man, Eur J Gastroenterol Hepatol 13: 25–29.
8. Francavilla R. Lionetti E. Castellaneta S. Magistà A. Maurogiovanni G. Bucci N. et al. (2008) Inhibition of Helicobacter pylori infection in humans by Lactobacillus reuteri ATCC 55730 and effect on eradication therapy: a pilot study. Helicobacter 13: 127–134.
9. Gill H. Rutherfurd K. Prasad J. Gopal P. (2000) Enhancement of natural and acquired immunity by Lactobacillus rhamnosus (HN001), Lactobacillus acidophilus (HN017) and Bifidobacterium lactis (HN019). Br J Nutr 83: 167–176.
10. Godoy A. Ribeiro M. Benvengo Y. Vitiello L. Miranda Mde C. Mendonça S. et al. (2003) Analysis of antimicrobial susceptibility and virulence factors in Helicobacter pylori clinical isolates. BMC Gastroenterol 3: 20.
11. Graham D. Opekun A. Klein P. (1993) Clarithromycin for the eradication of Helicobacter pylori. J Clin Gastroenterol 16: 292–4.
12. Hamilton-Miller J. (2003) The role of probiotics in the treatment and prevention of Helicobacter pylori infection. Int J Antimicrob Agents 22: 360–366.
13. Hunt R. Xiao S. Megraud F. Leon-Barua R. Bazzoli F. van der Merwe S. et al. (2011) Helicobacter pylori in developing countries. World Gastroenterology Organisation Global Guideline. J Gastrointestin Liver Dis 20: 299–304.
14. Ibrahim N. Gomaa A. Abu-Sief M. Hifnawy T. Tohamy M. (2012) The use of different laboratory methods in diagnosis of Helicobacter pylori infection; a comparative study Life Sci J 9: 249–259.
15. Johnston B. Supina A. Ospina M. Vohra S. (2008) Probiotics for the prevention of pediatric antibiotic-associated diarrhea. Evid.-Based Child Health 3: 280–315.
16. Kim J. Kim J. Kim N. Kim S. Jung H. Song I. (2006) Comparison of primary and secondary antimicrobial minimum inhibitory concentrations for Helicobacter pylori isolated from Korean patients. Int J Antimicrob Agents 28: 6–13.
17. Lionetti E. Miniello V. Castellaneta S. Magistá A. de Canio A. Maurogiovanni G. et al. (2006) Lactobacillus reuteri therapy to reduce side-effects during anti-Helicobacter pylori treatment in children: a randomized placebo controlled trial, Aliment Pharmacol Ther 24: 1461–1468.
18. Mack D. Michail S. Wei S. McDougall L. Hollingsworth M. (1999) Probiotics inhibit enteropathogenic E. coli adherence in vitro by inducing intestinal mucin gene expression. Am J Physiol 276: G941–G950.
19. Manfredi M. Bizzarri B. Sacchero R. Maccari S. Calabrese L. Fabbian F. et al. (2012) Helicobacter pylori infection in clinical practice: probiotics and a combination of probiotics + lactoferrin improve compliance, but not eradication, in sequential therapy. Helicobacter 17: 254–263.
20. Marshall B. Armstrong J. Francis G. Nokes N. Wee S. (1987) Antibacterial action of bismuth in relation to Campylobacter pyloridis colonization and gastritis. Digestion 37: 16–30.
21. Mégraud F. Coenen S. Versporten A. Kist M. Lopez-Brea M. Hirschl A. et al. (2013) Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption. Gut 62: 34–42.
22. Mégraud F. Lehours P. (2007) Helicobacter pylori detection and antimicrobial susceptibility testing. Clin Microbiol Rev 20: 280–283.
23. Njume C. Afolayan A. Ndip R. (2009) An overview of antimicrobial resistance and the future of medicinal plants in the treatment of Helicobacter pylori infections. Afr J Pharm Pharmacol 3: 685–699.
24. Ojetti V. Bruno G. Ainora M. Gigante G. Rizzo G. Roccarina D. et al. (2012) Impact of Lactobacillus reuteri supplementation on anti-Helicobacter pylori levofloxacin-based second-line therapy. Gastroenterol Res Pract 2012: 1–6.
25. Pantoflickova D. Corthesy-Theulaz I. Dorta G. Stolte M. Isler P. Rochat F. et al. (2003) Favorable effect of long-term intake of fermented milk containing Lactobacillus johnsonii on H. pylori associated gastritis, Aliment Pharmacol Ther 18: 805–813.
26. Price A. Misiewicz J. (1991) Sydney classification for gastritis. Lancet 337: 174.
27. Romano M. Cuomo A. (2004) Eradication of H. pylori: a clinical update. MedGenMed 6: 19.
28. Scaccianoce G. Zullo A. Hassan C. Gentili F. Cristofari F. Cardinale V. et al. (2008) Triple therapies plus different probiotics for Helicobacter pylori eradication. Eur Rev Med Pharmacol Sci 12: 251–256.
29. Seck A. Mbengue M. Gassama-Sow A. Diouf L. Ka M. Boye C. (2009) Antibiotic susceptibility of Helicobacter pylori isolates in Dakar, Senegal. J Infect Developing Countries 3: 137–140.
30. Spinler J. Taweechotipatr M. Rognerud C. Ou C. Tumwasorn S. Versalovic J. (2008) Human-derived probiotic Lactobacillus reuteri demonstrate antimicrobial activities targeting diverse enteric bacterial pathogens. Anaerobe 14: 166–171.
31. Stolte M. Batz C. Bayerdorffer E. Eidt S. (1995) Helicobacter pylori eradication in the treatment and differential diagnosis of giant folds in the corpus and fundus of the stomach. Z Gastroenterol 33: 198–201.
32. Svedlund J. Sjodin I. Dotevall G. (1988) GSRS: a clinical rating scale for gastrointestinal symptoms in patients with irritable bowel syndrome and peptic ulcer disease. Dig Dis Sci 33: 129–134.
33. Thomas C. Hong T. van Pijkeren J. Hemarajata P. Trinh D. Hu W. et al. (2012) Histamine derived from probiotic Lactobacillus reuteri suppresses TNF via modulation of PKA and ERK signaling. PloS ONE 7: e31951.
34. Thyagarajan S. Ray P. Das B. Ayyagari A. Khan A. Dharmalingam S. et al. (2003) Geographical difference in antimicrobial resistance pattern of Helicobacter pylori clinical isolates from Indian patients: multicentric study. J Gastroenterol Hepatol 18: 1373–1378.
35. Vaira D. Gatta L. Ricci C. D'anna L. Miglioli M. (2001) Helicobacter pylori: diseases, tests and treatment. Dig Liver Dis 33: 788–794.
36. Vakil N. Hahn B. McSorley D. (1998) Clarithromycin-resistant H. pylori in patients with duodenal ulcer in the United States. Am J Gastroenterol 93: 1432–1435.
37. Vitini E. Alvarez S. Medina M. Medici M. de Budeguer M. Perdigon G. (2000) Gut mucosal immunostimulation by lactic acid bacteria. Biocell 24: 223–232.
38. Wang K. Li S. Liu C. Perng D. Su Y. Wu D. et al. (2004) Effects of ingesting Lactobacillus and Bifidobacterium-containing yoghurt in subjects with colonized Helicobacter pylori, Am J Clin Nutr 80: 737–741.
39. Yaşar B. Abut E. Kayadıb H. Toros B. Sezıkl M. Akkan Z. et al. (2010) Efficacy of probiotics in Helicobacter pylori eradication therapy. Turk J Gastroenterol 21: 212–217.